Aarti Drugs has informed about the Statement of Investor Complaints as per Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30th June, 2017.
The above information is a part of company’s filings submitted to BSE.